Classes
DEA Class; Rx
Common Brand Names; Cytosar U, DepoCyt
- Antineoplastics, Antimetabolite
Description
Pyrimidine antimetabolite anitneoplastic agent; used in the treatment of hematologic malignancies; has limited cytotoxicity in solid tumors; a liposomal product is also available
Indications
Indicated for the treatment of acute myelogenous leukemia (AML).
Contraindications
Hypersensitivity
Liposomal cytarabine: active meningeal infection
Adverse Effects
- Anorexia
- Nausea
- Vomiting
- Diarrhea
- Oral/anal inflammation
- Thrombophlebitis
- Bleeding
- Myelosuppression
- Rash
- Fever
- Hepatic dysfunction
- Headache
- Neuropathy
- Chest pain
- Pericarditis
- Pneumonia
- Anemia
- Bleeding
- Leukopenia
- Thrombocytopenia
- Kidney disease
- Infectious disease
- Sepsis
- “Cytarabine syndrome”: fever, myalgia, bone pain, rash, conjunctivitis, malaise
- Skin ulcers
- Cellulitis
Warnings
Potent bone marrow suppression
Severe and at times fatal CNS, GI, and pulmonary toxicity
Cardiomyopathy with subsequent death reported following experimental high dose therapy with cytarabine in combination with cyclophosphamide when used for bone marrow transplant preparation
Do not use benzyl alcohol-containing solutions IT or in neonates
Avoid pregnancy
Pregnancy and Lactation
Pregnancy Category: D
Lactation: not known if excreted in breast milk, avoid
Maximum Dosage
6 g/m2/day IV; 100 mg/m2/day SC; 70 mg/m2 intrathecally.
6 g/m2/day IV; 100 mg/m2/day SC; 70 mg/m2 intrathecally.
6 g/m2/day IV; 100 mg/m2/day SC; 70 mg/m2 intrathecally.
6 g/m2/day IV; 100 mg/m2/day SC; 70 mg/m2 intrathecally.
How supplied
Cytarabine
injectable solution
- 10mg/mL
- 20mg/mL
- 100mg/mL
intrathecal injection, liposomal (DepoCyt)
- 50mg/5mL
powder for injection
- 100mg/vial
- 500mg/vial
- 1g/vial
- 2g/vial